Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDYL | Q9Y232 | 3/20 | 0.60 |
| ▸ | CBX7 | O95931 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.54 |
| ▸ | BRD4 | O60885 | 3/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.45 |
| ▸ | CDYL2 | Q8N8U2 | 2/20 | 0.44 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3969763 | 0.90 | TP53 (0.62) | CDYLCBX7TP53MDM2BRD4 | |
| SCHEMBL4590472 | 0.88 | CBX7 (0.52) | CDYLCBX7TP53MDM2BRD4 | |
| SCHEMBL2497114 | 0.86 | KDM4E (0.52) | CDYLCBX7TP53MDM2BRD4 | |
| SCHEMBL2498528 | 0.86 | BRD4 (0.57) | CDYLCBX7BRD4SCN9AIDO1 | |
| SCHEMBL24280978 | 0.84 | KMT2A (0.59) | CDYLCBX7TP53MDM2BRD4 | |
| SCHEMBL4590146 | 0.84 | CDYL (0.56) | CDYLCBX7TP53MDM2BRD4 | |
| SCHEMBL27681626 | 0.82 | CDYL (0.55) | CDYLCBX7TP53MDM2BRD4 | |
| SCHEMBL2497407 | 0.81 | BRD4 (0.52) | CDYLCBX7BRD4PGRIDO1 | |
| SCHEMBL27503441 | 0.81 | BRD4 (0.44) | CDYLCBX7TP53MDM2BRD4 | |
| SCHEMBL2493174 | 0.81 | KMT2A (0.55) | CDYLCBX7BRD4PGRIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-7425566-B2 | 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2008-09-16 | — | — | US | disclosed |
| CN-101018778-A | Substituted oxindole derivatives and medicaments containing them | ABBOTT GMBH & CO KG (DE) | 2007-08-15 | — | — | CN | disclosed |
| US-20050176770-A1 | Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
| CN-1193025-C | 1, 3-dihydro-2H-indol-2-one derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI SYNTHELABO (FR) | 2005-03-16 | — | — | CN | disclosed |
| US-6864277-B2 | 1,3-dihydro-2H-indol-2-one derivatives, method for preparing same and pharmaceutical compositions containing them | SANOFI-SYNTHELABO (FR) | 2005-03-08 | — | — | US | disclosed |
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | SANOFI-AVENTIS (FR) | 2003-08-28 | — | — | US | disclosed |
| CN-1404479-A | 1, 3-dihydro-2H-indol-2-one derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI SYNTHELABO (FR) | 2003-03-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | AVPR1B, AVPR1A, AVPR2 | CDYL 4544/4885CBX7 4049/4885TP53 986/4885 |
| US-20050176770-A1 | Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | AVPR1B, AVPR2, AVPR1A | CDYL 3213/4885CBX7 3930/4885TP53 1062/4885 |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | CDYL 3793/4885CBX7 4226/4885TP53 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.